Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for long‑term management of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory support across multiple regions.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms.

- Asthma maintenance therapy: reduces frequency of asthma attacks and improves overall control in patients with persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways that can occur during or after physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions - Angioedema affecting face, lips or throat - Mood changes, including depression or suicidal thoughts - Elevated liver enzymes or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic pneumonia

When prescribing Montelukast, clinicians should consider several safety and handling precautions.

- Assess liver function: monitor hepatic enzymes in patients with existing liver disease. - Review psychiatric history: observe for mood alterations or suicidal ideation, especially in adolescents. - Evaluate for hypersensitivity: discontinue if signs of severe allergic reaction appear. - Consider drug interactions: adjust therapy when used with strong enzyme inducers or inhibitors. - Use caution in pregnancy: discuss potential risks and benefits with the patient. - Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may markedly lower montelukast plasma concentrations, reducing therapeutic effect. - Rifampin: strong enzyme inducer that can decrease montelukast exposure. - Ketoconazole: potent CYP3A4 inhibitor that may raise montelukast levels and risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as montelukast may affect anticoagulation control. - Beta‑agonists: concurrent use may increase risk of bronchospasm or tachycardia. - ACE inhibitors: observe for enhanced cough or angioedema when combined.